Literature DB >> 28347236

High mobility group box 1/toll-like receptor 4/myeloid differentiation factor 88 signaling promotes progression of gastric cancer.

Yanqiu Yue1, Tao Zhou1, Yanjing Gao1, Zongli Zhang2, Li Li3, Lin Liu3, Wenna Shi4, Lihui Su1, Baoquan Cheng1.   

Abstract

High mobility group box 1 and toll-like receptor 4/myeloid differentiation factor 88 signaling pathway have been indicated to have oncogenic effects in many cancers. However, the role of high mobility group box 1/toll-like receptor 4/myeloid differentiation factor 88 signaling pathway in the development of gastric cancer remains unclear. In this study, we demonstrated that high mobility group box 1, toll-like receptor 4, and myeloid differentiation factor 88 were overexpressed in gastric cancer tumors compared with the adjacent non-tumor tissues. The overexpression of high mobility group box 1, toll-like receptor 4, and myeloid differentiation factor 88 were correlated with tumor-node-metastasis stage (p = 0.0068, p = 0.0063, p = 0.0173) and lymph node metastasis (p = 0.0272, p = 0.0382, and p = 0.0495). Furthermore, we observed that knockdown of high mobility group box 1 by high mobility group box 1-small interfering RNA suppressed the expression of toll-like receptor 4 and myeloid differentiation factor 88. Blockage of high mobility group box 1/toll-like receptor 4/myeloid differentiation factor 88 signaling by high mobility group box 1-small interfering RNA resulted in elevation of apoptotic ratio and inhibition of cell growth, migration, and invasion by upregulating Bax expression and downregulating Bcl-2, matrix metalloproteinase-2, nuclear factor kappa B/p65 expression, and the nuclear translocation of nuclear factor kappa B/p65 in gastric cancer cells. Our findings suggest that high mobility group box 1/toll-like receptor 4/myeloid differentiation factor 88 signaling pathway may contribute to the development and progression of gastric cancer via the nuclear factor kappa B pathway and it also represents a novel potential therapeutic target for gastric cancer.

Entities:  

Keywords:  High mobility group box 1; gastric cancer; invasion; myeloid differentiation factor 88; proliferation; toll-like receptor 4

Mesh:

Substances:

Year:  2017        PMID: 28347236     DOI: 10.1177/1010428317694312

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  6 in total

Review 1.  The RAGE/multiligand axis: a new actor in tumor biology.

Authors:  Armando Rojas; Ivan Schneider; Cristian Lindner; Ileana Gonzalez; Miguel A Morales
Journal:  Biosci Rep       Date:  2022-07-29       Impact factor: 3.976

2.  Downregulation of high mobility group box 1 enhances the radiosensitivity of non-small cell lung cancer by acting as a crucial target of microRNA-107.

Authors:  Lu Bai; Jingjing Zhang; Dongqi Gao; Chengyi Liu; Wenxin Li; Qingshan Li
Journal:  Exp Ther Med       Date:  2021-04-25       Impact factor: 2.447

3.  Expression and Significance of MyD88 in Patients With Gastric Cardia Cancer in a High-Incidence Area of China.

Authors:  Jingyao Chen; Di Xia; Muming Xu; Ruibing Su; Wenting Lin; Dan Guo; Guangcan Chen; Shuhui Liu
Journal:  Front Oncol       Date:  2020-05-14       Impact factor: 6.244

Review 4.  Immune targets in the tumor microenvironment treated by radiotherapy.

Authors:  Omer M Ozpiskin; Lu Zhang; Jian Jian Li
Journal:  Theranostics       Date:  2019-01-30       Impact factor: 11.556

5.  Validity of serum amyloid A and HMGB1 as biomarkers for early diagnosis of gastric cancer.

Authors:  Ali A Ghweil; Heba A Osman; Mohammed H Hassan; Abeer Mm Sabry; Reem E Mahdy; Ahmed Rh Ahmed; Ahmed Okasha; Ashraf Khodeary; Hesham H Ameen
Journal:  Cancer Manag Res       Date:  2020-01-08       Impact factor: 3.989

6.  Aberrant expression of MYD88 via RNA-controlling CNOT4 and EXOSC3 in colonic mucosa impacts generation of colonic cancer.

Authors:  Masumi Tsuda; Misa Noguchi; Tsuyoshi Kurai; Yuji Ichihashi; Koki Ise; Lei Wang; Yusuke Ishida; Mishie Tanino; Satoshi Hirano; Masahiro Asaka; Shinya Tanaka
Journal:  Cancer Sci       Date:  2021-10-25       Impact factor: 6.716

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.